Powered by lexis nexis

GUMC announces launch of Phase II Parkinson's disease trial

Feb 27, 2017 - Marketline Newswire

Georgetown University Medical Center (GUMC) has announced the launch of a Phase II clinical trial to study the safety of the cancer drug nilotinib and its effects on clinical outcomes and biomarkers in people with Parkinson's disease.

GUMC is recruiting volunteers for the study in collaboration with its clinical partner, MedStar Georgetown University Hospital. The clinical trial is a Phase II, randomized, double-blind, placebo-controlled study designed to evaluate the safety and tolerabili...